Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report.

Authors :: De Novellis D
Zeppa P
Maffei E
Giudice V
Selleri C
Serio B
Source :: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2024 Nov; Vol. 7 (11), pp. e2149.
Publication Year :: 2024
Abstract: Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.<br />Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.<br />Conclusions: We showed the efficacy of daratumumab in combination with targeted therapies for the treatment of pulmonary MM.<br /> (© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.)

Subjects :: Humans
Male
Middle Aged
Treatment Outcome
Multiple Myeloma drug therapy
Multiple Myeloma pathology
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal administration & dosage
Lung Neoplasms drug therapy
Lung Neoplasms pathology
Lung Neoplasms genetics
Plasmacytoma drug therapy
Plasmacytoma pathology
Plasmacytoma diagnosis
Plasmacytoma therapy
Antineoplastic Combined Chemotherapy Protocols therapeutic use

Full Text Access

Tools